<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587181</url>
  </required_header>
  <id_info>
    <org_study_id>01-04/18</org_study_id>
    <nct_id>NCT03587181</nct_id>
  </id_info>
  <brief_title>Investigation of Substrates Associated With the Recurrence of Atrial Fibrillation After PV Cryoablation</brief_title>
  <acronym>SubstrateAF</acronym>
  <official_title>Investigation of Substrates Associated With the Recurrence of Atrial Fibrillation After PV Cryoablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Center for Preventive Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>I.M. Sechenov First Moscow State Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Medical Research Center for Therapy and Preventive Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The two main mechanisms for atrial fibrillation (AF) recurrence after cryoablation include&#xD;
      Pulmonary vein (PV) reconnection and the presence of non-PV associated arrhythmic focuses.&#xD;
      The aim of this study is to investigate the prevalence of each mechanism and if biomarkers&#xD;
      may be used to predict of these events.&#xD;
&#xD;
      Eighty patients with paroxysmal or persistent AF will undergo PV isolation with cryoablation&#xD;
      followed by loop recorder implantation. Patients in whom atrial tachyarrhythmias recur during&#xD;
      12 months follow-up (outside of the 3-month post procedure blanking window) will be offered a&#xD;
      second electrophysiology study (EP) study to assess PV isolation and non-PV focuses and&#xD;
      further ablation performed as required.&#xD;
&#xD;
      At baseline blood samples will be taken to investigate the correlation between specific&#xD;
      biomarkers and both the incidence and type of recurrence. The correlation between recurrence&#xD;
      of atrial tachyarrhythmias due to non-PV associated arrhythmic focuses and elevated baseline&#xD;
      levels of NT-ProBNP, CRP, TNF, MMP1 will be pre-specified.&#xD;
&#xD;
      40 consecutive patients will have a biopsy taken from the intraventricular and interatrial&#xD;
      septum to investigate the correlation between myocardial inflammation, the presence of&#xD;
      fibrosis and recurrence of atrial tachyarrhythmias. Correlation between biomarkers of&#xD;
      inflammation and biopsy-proven myocardial inflammation or fibrosis will be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The two main mechanisms for atrial fibrillation (AF) recurrence after cryoablation include&#xD;
      Pulmonary vein (PV) reconnection and the presence of non-PV associated arrhythmic focuses.&#xD;
      The aim of this study is to investigate the prevalence of each mechanism and if biomarkers&#xD;
      may be used to predict these events.&#xD;
&#xD;
      Eighty patients with paroxysmal or persistent AF will undergo PV isolation with cryoablation&#xD;
      followed by loop recorder implantation. Patients in whom atrial tachyarrhythmias recur during&#xD;
      12 months follow-up (outside of the 3-month post procedure blanking window) will be offered a&#xD;
      second EP study to assess PV isolation and non-PV focuses and further ablation performed as&#xD;
      required. Recurrence will be defined as an episode of atrial tachyarrhythmia (AF, atypical&#xD;
      atrial flutter, or atrial tachycardia) on loop recorder with a duration greater than 30&#xD;
      seconds or ECG document atrial tachyarrhythmia. The incidence of atrial tachyarrhythmia&#xD;
      recurrence, and its association with symptoms after the index PV cryoballoon isolation, will&#xD;
      be assessed.&#xD;
&#xD;
      At baseline blood samples will be taken to assess levels of N-terminal pro brain natriuretic&#xD;
      peptide (NT-proBNP), High-sensitivity C-reactive protein (high-sensitive CRP), Tumor Necrosis&#xD;
      Factor (TNF), Interleukin 1 beta (IL1B), Fatty acid binding protein (FABP), Matrix&#xD;
      metalloproteinase-1 (MMP1), Matrix metalloproteinase-3 (MMP3), Matrix metalloproteinase-9&#xD;
      (MMP9), Transforming growth factor beta 1 (TGF-beta1), Tissue inhibitor of metalloproteinases&#xD;
      1 (TIMP-1), Fibroblast growth factor 9 (FGF-9). Correlation between recurrence of atrial&#xD;
      tachyarrhythmias due to non-PV associated arrhythmic focuses and elevated baseline levels of&#xD;
      NT-ProBNP, CRP, TNF, MMP1 will be pre-specified. We will look with receiver operating&#xD;
      characteristic (ROC) curve analysis the level of biomarkers which predict recurrence of&#xD;
      atrial tachyarrhythmias with the best ratio between sensitivity and specificity.&#xD;
&#xD;
      40 consecutive patients will have a biopsy taken from the intraventricular and interatrial&#xD;
      septum to investigate the correlation between myocardial inflammation, the presence of&#xD;
      fibrosis and recurrence of atrial tachyarrhythmias. Correlation between biomarkers of&#xD;
      inflammation and biopsy-proven myocardial inflammation or fibrosis will be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2017</start_date>
  <completion_date type="Actual">October 30, 2019</completion_date>
  <primary_completion_date type="Actual">October 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial tachyarrhythmia recurrence</measure>
    <time_frame>1 year</time_frame>
    <description>Atrial tachyarrhythmias recurrence by ECG, Holter monitoring or loop recorder after 3 months of blanking period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The prevalence of PV reconnection and non-PV focuses as substrate of atrial tachyarrhythmia after cryoablation</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in baseline NT-ProBNP levels between those patients with recurrence of atrial tachyarrhythmias due to non-PV associated arrhythmic focuses and those without at 12 months</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in baseline CRP levels between those patients with recurrence of atrial tachyarrhythmias due to non-PV associated arrhythmic focuses and those without at 12 months</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in baseline TNF levels between those patients with recurrence of atrial tachyarrhythmias due to non-PV associated arrhythmic focuses and those without at 12 months</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in baseline MMP1 levels between those patients with recurrence of atrial tachyarrhythmias due to non-PV associated arrhythmic focuses and those without at 12 months</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference in baseline NT-ProBNP levels between those patients with recurrence of atrial tachyarrhythmias and those without at 12 months</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoablation of the pulmonary veins and myocardial biopsy</intervention_name>
    <description>Before intervention blood samples will be collected for biobank storage. After left atrial appendage thrombus exclusion, a cardiac biopsy from intraventricular and interatrial septum will be performed. PV isolation will be performed with cryoablation. Successful PV isolation will be confirmed by the confirmation of bi-directional block. Phrenic nerve function will be assessed in a standard fashion during intervention of the right PVs using high output phrenic nerve pacing from the superior vena cava. Loop recorder implantation will be performed during the same procedure.&#xD;
In patients with recurrent atrial tachyarrhythmias an EP study will be performed to assess the mechanism of recurrence. PV reconnections will be re-isolated and linear lesions performed as required.</description>
    <other_name>loop recorder implantation</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Before intervention blood samples will be collected for biobank storage. It is planned to&#xD;
      assess levels of NT-proBNP, high-sensitive CRP, TNF, IL1B, FABP, MMP1, MMP3, MMP9, TGF-beta1,&#xD;
      TIMP-1, FGF-9.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 18-80 years old with symptomatic paroxismal or persistant atrial fibrillation&#xD;
        (EHRA scale 2b-4)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ Patient with paroxysmal/persistent atrial fibrillation (EHRA scale 2b-4)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prior interventions for AF&#xD;
&#xD;
          -  permanent AF&#xD;
&#xD;
          -  contraindications to oral anticoagulation or heparin&#xD;
&#xD;
          -  chronic kidney disease requiring dialysis&#xD;
&#xD;
          -  untreated hypo- or hyperthyroidism&#xD;
&#xD;
          -  breast feeding&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  chronic kidney disease requiring dialysis&#xD;
&#xD;
          -  decompensated heart failure&#xD;
&#xD;
          -  stroke within the last 3 months&#xD;
&#xD;
          -  myocardial infarction within the last 3 months&#xD;
&#xD;
          -  Percutaneous coronary intervention or Coronary Artery Bypass Grafting within the last&#xD;
             3 months&#xD;
&#xD;
          -  active myocarditis&#xD;
&#xD;
          -  artificial valve replacement surgery&#xD;
&#xD;
          -  severe mitral or aortic stenosis&#xD;
&#xD;
          -  coronary artery disease requiring revascularization&#xD;
&#xD;
          -  heart transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Research Center for Preventive Medicine</name>
      <address>
        <city>Moscow</city>
        <zip>101990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cryoballoon, Cryoablation, biobanking, Loop recorder, biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

